Delaware Business DE

AstraZeneca inks potential $6.9 cancer drug deal with Japanese company

Delaware Business Now

Mar 29, 2019

AstraZeneca is betting big on with a potential $6.9 billion agreement with Daiichi Sankyo Company for trastuzumab, a promising medicine for cancer treatment. The company will help…

Read the full story at Delaware Business Now

AstraZeneca inks potential $6.9 cancer drug deal with Japanese company

More from Delaware Business

Delaware charters pulled for LLC's tied to drug traffickers

Delaware gas prices approach year-ago numbers

Rack Room Shoes opens in Salisbury, and a new pool hall on the way | What's Going There

Suspect dead after carjackings, pursuit by officers in I-95 area

PBF Energy acquires remaining interests in logistics business

My take: Feds take closer look at criminal monopoly actions

ChristianaCare center named in honor of donor and breast cancer survivor Tatiana Copeland

Veteran Business Leader and Communications Specialist to Assume Role of Vice Chair